Eight out of fourteen evaluable advanced breast cancer patients demonstrated a consistent or increased quantity of CTCs in 7.5 ml blood following the first cycle of Lapatinib treatment.

<p>Graphs show CTC measurements and EGFR positivity at screening or baseline and at follow-up after Lapatinib treatment in each patient (A – H). Seven patients also showed an increase in EGFR positive CTCs after Lapatinib treatment (B, C, D, E, F, G and H). Serial CTCs were taken with ethical approval (07/Q0401/20) and additional consent.